Odor identification impairment and cholinesterase inhibitor treatment in Alzheimer's disease.

ABSTRACT:

Introduction

This study evaluated acute change in odor identification following atropine nasal spray challenge, and 8-week change in odor identification ability, as a predictor of long-term improvement in patients with mild to moderate Alzheimer's disease (AD) who received open-label cholinesterase inhibitor treatment.

Methods

In patients with clinical AD, the University of Pennsylvania Smell identification Test (UPSIT) was administered before and after an anticholinergic atropine nasal spray challenge. Patients were then treated with donepezil for 52 weeks.

Results

In 21 study participants, acute atropine-induced decrease in UPSIT was not associated with change in the Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) or Selective Reminding Test (SR

SUBMITTER: Motter JN 

PROVIDER: S-EPMC8010480 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature